Get the Stockscreener App
128.81
0.70%
0.95
After Hours:
128.96
0.15
+0.12%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $128.81, with a volume of 5.72M.
It is up +0.70% in the last 24 hours and up +14.15% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$127.86
Open:
$127.99
24h Volume:
5.72M
Relative Volume:
1.11
Market Cap:
$223.55B
Revenue:
$41.95B
Net Income/Loss:
$13.40B
P/E Ratio:
16.84
EPS:
7.65
Net Cash Flow:
$6.49B
1W Performance:
+4.50%
1M Performance:
+14.15%
6M Performance:
+22.26%
1Y Performance:
+13.46%
1-Day Range:
$127.19
$129.19
1-Week Range:
$122.18
$129.85
52-Week Range:
$99.71
$129.85
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
128.81 | 223.55B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
103.05 | 152.39B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
390.43 | 149.22B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
91.99 | 118.43B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
73.22 | 43.46B | 6.60B | 4.16B | 490.10M | 6.93 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories (NYSE:ABT) Stock Holdings Lowered by New England Research & Management Inc. - MarketBeat
Robeco Institutional Asset Management B.V. Acquires 235,790 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Asset Dedication LLC Sells 8,658 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
India Medical Nutrition Market Set to Witness Significant Growth by 2025-2032:Abbott Laboratories,Danone - EIN News
Abbott Laboratories (ABT): How Hot Money Found Its Way Into This Healthcare Giant - Insider Monkey
Jim Cramer Says Abbott Laboratories (ABT) ‘Was The Market Leader Yesterday. That’s New’ - Insider Monkey
New Abbott medical device course at PVAMU introduces students to medical device careers - Prairie View A&M University
Swedbank AB Sells 547,307 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Hantz Financial Services Inc. Cuts Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Orca Wealth Management LLC Acquires New Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Pacer Advisors Inc. Sells 6,817 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Kingswood Wealth Advisors LLC Sells 11,189 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Labs Reports Strong Growth Despite Challenges - TipRanks
Abbott Laboratories stock outperforms competitors despite losses on the day - MarketWatch
9 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Nephron Research Adjusts Abbott Laboratories Price Target to $135 From $120 -January 28, 2025 at 09:15 am EST - Marketscreener.com
Perigon Wealth Management LLC Grows Stake in Abbott Laboratories (NYSE:ABT) - MarketBeat
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - Yahoo Finance
Hutchens & Kramer Investment Management Group LLC Acquires New Shares in Abbott Laboratories (NYSE:ABT) - MarketBeat
Argus Adjusts Price Target on Abbott Laboratories to $150 From $145 -January 28, 2025 at 08:27 am EST - Marketscreener.com
BankPlus Wealth Management LLC Takes Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (NYSE:ABT) Shares Purchased by Nilsine Partners LLC - MarketBeat
The Art of Valuation: Discovering Abbott Laboratories's Intrinsi - GuruFocus.com
The Art of Valuation: Discovering Abbott Laboratories's Intrinsic Value - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Shares Sold by Exchange Traded Concepts LLC - MarketBeat
Abbott Laboratories stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
The Zacks Analyst Blog Highlights Cisco Systems, Abbott Laboratories and Coca-Cola - Yahoo Finance
Paul MacDonald's Past Picks: Stryker, Abbott Laboratories and Elevance Health - BNN Bloomberg
NMDP Strengthens Executive Leadership Team - GlobeNewswire Inc.
This Is What Whales Are Betting On Abbott Laboratories - Benzinga
Abbott Laboratories: A Significant Addition to Eaton Vance Worldwide Health Sciences Fund - Yahoo Finance
Biological Drugs Strategic Research Report 2024-2030, - GlobeNewswire
Baldwin Wealth Partners LLC MA Sells 2,659 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (NYSE:ABT) Shares Bought by Parsons Capital Management Inc. RI - MarketBeat
North Point Portfolio Managers Corp OH Sells 3,043 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (NYSE:ABT) Given "Overweight" Rating at Barclays - MarketBeat
Barclays raises Abbott Labs stock price target to $158 - MSN
WST, GXIG, STVN poised to benefit from Abbott's CGM growth - Investing.com
KBC Group NV Has $108.88 Million Stock Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Blue Trust Inc. Acquires 4,316 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Union Bancaire Privee UBP SA Makes New Investment in Abbott Laboratories (NYSE:ABT) - MarketBeat
Narwhal Capital Management Has $5.82 Million Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories' (NYSE:ABT) large institutional owners must be happy as stock continues to impress, up 10% over the past week - Yahoo Finance
Is There More Upside For ABT Stock After A 10% Jump In A Week? - Forbes
Abbott Laboratories: Strong Q4 Results And Bullish Outlook - Seeking Alpha
Jim Cramer Recommends Abbott Laboratories (ABT) – ‘Their Legal Stuff Is Largely Behind Them’ - MSN
Jamison Private Wealth Management Inc. Grows Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Moody Lynn & Lieberson LLC Grows Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
The Motley Fool: A diverse health care dynamo - The Dallas Morning News
Dynamic Advisor Solutions LLC Lowers Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
SG Americas Securities LLC Has $3.81 Million Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):